This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Adma Biologics (ADMA) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
Adma Biologics (ADMA) delivered earnings and revenue surprises of 22.22% and 8.77%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
Beam Therapeutics Inc. (BEAM) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
Beam Therapeutics Inc. (BEAM) delivered earnings and revenue surprises of 5.56% and 26.87%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
VistaGen Therapeutics, Inc. (VTGN) Reports Q4 Loss, Misses Revenue Estimates
by Zacks Equity Research
VistaGen Therapeutics, Inc. (VTGN) delivered earnings and revenue surprises of -33.33% and 88.18%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Nurix Therapeutics, Inc. (NRIX) Soars 14.5%: Is Further Upside Left in the Stock?
by Zacks Equity Research
Nurix Therapeutics, Inc. (NRIX) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
Bristol Myers' (BMY) Opdivo Data Positive for Neoadjuvant NSCLC
by Zacks Equity Research
Bristol Myers (BMY) posts favorable data from a late-stage study that shows neoadjuvant Opdivo with chemotherapy to significantly better the event-free survival rate in patients with resectable NSCLC.
Gilead (GILD) Magrolimab Studies' Partial Clinical Hold Removed
by Zacks Equity Research
Gilead (GILD) studies evaluating its investigational agent magrolimab in combination with Vidaza are no longer under FDAs partial clinical hold.
Novartis (NVS) Anti-PD-1 Drug Validated by EMA for Lung Cancer
by Zacks Equity Research
Novartis (NVS) application seeking approval of tislelizumab in multiple non-small cell lung cancer and esophageal squamous cell carcinoma indications gets EMA's validation.
Bristol Myers (BMY) Gets EC Nod for Opdivo's Label Expansion
by Zacks Equity Research
Bristol Myers (BMY) receives EC approval for label expansion of Opdivo for ESCC and urothelial carcinoma.
VistaGen Therapeutics, Inc. (VTGN) Reports Q3 Loss, Tops Revenue Estimates
by Zacks Equity Research
VistaGen Therapeutics, Inc. (VTGN) delivered earnings and revenue surprises of 37.50% and 8.49%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
Earnings Preview: VistaGen Therapeutics, Inc. (VTGN) Q3 Earnings Expected to Decline
by Zacks Equity Research
VistaGen Therapeutics, Inc. (VTGN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
VistaGen Therapeutics, Inc. (VTGN) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
VistaGen Therapeutics, Inc. (VTGN) delivered earnings and revenue surprises of -40.00% and 9.48%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?
Will VistaGen Therapeutics, Inc. (VTGN) Report Negative Q2 Earnings? What You Should Know
by Zacks Equity Research
VistaGen Therapeutics, Inc. (VTGN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Sage, Biogen Plan to File Zuranolone NDA for MDD in 2022
by Zacks Equity Research
Sage (SAGE) and partner Biogen are looking to get approval for zuranolone as an oral treatment for major depressive disorder. They will start rolling submission of an NDA in early 2022 for the candidate.
VistaGen Therapeutics, Inc. (VTGN) Reports Q1 Loss, Misses Revenue Estimates
by Zacks Equity Research
VistaGen Therapeutics, Inc. (VTGN) delivered earnings and revenue surprises of 20.00% and -4.58%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?
Sage Stock Declines on Late-Stage Depression Study Data
by Zacks Equity Research
Sage is developing zuranolone as a potential treatment for major depression disorder in late-stage studies.
New Strong Sell Stocks for March 11th
by Zacks Equity Research
Here are 5 stocks added to the Zacks Rank #5 (Strong Sell) List today
VistaGen Therapeutics, Inc. (VTGN) Reports Q3 Loss, Lags Revenue Estimates
by Zacks Equity Research
VistaGen Therapeutics, Inc. (VTGN) delivered earnings and revenue surprises of -40.00% and -4.85%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?
VistaGen Up on Fast Track Designation for Anxiety Disorder Drug
by Zacks Equity Research
The FDA assigns a Fast Track status to VistaGen's (VTGN) neuroactive nasal spray PH94B for the on-demand treatment of social anxiety disorder. Stock surges.
Sage Therapeutics' Depression Drug Fails in Study, Stock Down
by Zacks Equity Research
Sage Therapeutics' (SAGE) phase III study on pipeline candidate SAGE-217 for the treatment of major depressive disorder fails to meet the primary endpoint.
Biotech Stock Roundup: MYOV & KRTX Surge, Pipeline Updates From VRTX, CELG & More
by Zacks Equity Research
Key highlights of the past week include regulatory and pipeline updates along with collaboration deals.
VistaGen's (VTGN) Major Depressive Disorder Drug Disappoints
by Zacks Equity Research
VistaGen (VTGN) announces disappointing results from the ELEVATE study on MDD candidate, AV-101.
Biotech Stock Roundup: GILD, BIIB Present Data, VTGN Gains on Fast Track Status
by Zacks Equity Research
Data presentations by leading sector players take center stage this week.
VistaGen Up on Fast Track Designation to Pain Candidate
by Zacks Equity Research
VistaGen (VTGN) Fast Track designation for its pipeline candidate, AV-101, for treating neuropathic pain.
3 Drug/Biotech Stocks Up More Than 10% This Week
by Zacks Equity Research
The drugs/biotech sector is down this week due to broader market pressure, except a few stocks.
3 Drug/Biotech Stocks Up More Than 10% This Week
by Zacks Equity Research
The drugs/biotech sector is down this week due to broader market pressure, except a few stocks.